Literature DB >> 16968797

Differences in follicle-stimulating hormone secretion between 45,X monosomy Turner syndrome and 45,X/46,XX mosaicism are evident at an early age.

Patricia Y Fechner1, Marsha L Davenport, Rebecca L Qualy, Judith L Ross, Daniel F Gunther, Erica A Eugster, Carol Huseman, Anthony J Zagar, Charmian A Quigley.   

Abstract

CONTEXT: Little information exists regarding FSH values in very young girls with Turner syndrome (TS).
OBJECTIVES: The objective of the study was to evaluate the pattern, natural progression, and karyotype-related differences in FSH secretion in young, prepubertal girls with TS. STUDY
DESIGN: FSH was measured at study entry and annually for 2 yr.
SETTING: The Toddler Turner study was conducted at 11 U.S. pediatric endocrine centers. STUDY PARTICIPANTS: Eighty-eight girls with karyotype-proven TS aged 9 months to 4 yr participated in the study. MAIN OUTCOME MEASURES: By-karyotype differences in FSH concentration and age-related changes in FSH were measured.
RESULTS: Mean (+/- SD) FSH was markedly elevated in the 45,X (n = 56: 68.3 +/- 36.0 IU/liter) and Other groups [n = 15 (excluding three subjects with Y-containing karyotypes): 52.7 +/- 50.8 IU/liter] but was minimally elevated in girls with 45,X/46,XX mosaicism (n = 14: 10.1 +/- 13.5 IU/liter, P < 0.005 both comparisons). Over the 2-yr period, FSH declined in the 45,X group (-13.4 IU/liter.yr, P < 0.0001). Nonetheless, only three of 159 FSH values fell within normal range for age at any time during the 2-yr study. FSH decline was similar in the Other group (-14.3 IU/liter.yr, P = 0.0032). In contrast, no significant decrease in FSH with age was observed in the 45,X/46,XX group.
CONCLUSIONS: In contrast to the original report of FSH concentrations in individuals with TS, this study demonstrates distinct differences in patterns of FSH secretion between young girls with monosomy TS, who have persistent elevation of FSH to age 6 yr, and those with 45,X/46,XX mosaicism, whose FSH values suggest retained ovarian function in the majority. These findings have implications for patient management and family counseling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968797     DOI: 10.1210/jc.2006-1157

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

Review 2.  The Hypothesis of the Prolonged Cell Cycle in Turner Syndrome.

Authors:  Francisco Álvarez-Nava; Marisol Soto-Quintana
Journal:  J Dev Biol       Date:  2022-05-11

Review 3.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2009-12       Impact factor: 4.741

Review 4.  Genetic defects of ovarian TGF-β-like factors and premature ovarian failure.

Authors:  L Persani; R Rossetti; C Cacciatore; S Fabre
Journal:  J Endocrinol Invest       Date:  2011-02-04       Impact factor: 4.256

5.  Mosaic triple X syndrome in a female with primary amenorrhea.

Authors:  A Venkateshwari; K Srimanjari; A Srilekha; Ashrafunnisa Begum; M Sujatha; T Sunitha; Pratibha Nallari; A Jyothy
Journal:  Indian J Hum Genet       Date:  2012-05

6.  Turner syndrome and sexual differentiation of the brain: implications for understanding male-biased neurodevelopmental disorders.

Authors:  Rebecca Christine Knickmeyer; Marsha Davenport
Journal:  J Neurodev Disord       Date:  2011-08-05       Impact factor: 4.025

Review 7.  Up-To-Date Review About Minipuberty and Overview on Hypothalamic-Pituitary-Gonadal Axis Activation in Fetal and Neonatal Life.

Authors:  Lucia Lanciotti; Marta Cofini; Alberto Leonardi; Laura Penta; Susanna Esposito
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-23       Impact factor: 5.555

Review 8.  Delayed Puberty-Phenotypic Diversity, Molecular Genetic Mechanisms, and Recent Discoveries.

Authors:  Sasha R Howard; Leo Dunkel
Journal:  Endocr Rev       Date:  2019-10-01       Impact factor: 19.871

9.  Recombinant human growth hormone in the treatment of Turner syndrome.

Authors:  Bessie E Spiliotis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

10.  Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome.

Authors:  Chiara Castronovo; Raffaella Rossetti; Daniela Rusconi; Maria P Recalcati; Chiara Cacciatore; Elena Beccaria; Valeria Calcaterra; Pietro Invernizzi; Daniela Larizza; Palma Finelli; Luca Persani
Journal:  Hum Reprod       Date:  2013-12-08       Impact factor: 6.918

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.